Kalanchoe crenata 安德鲁斯 (Haw.) 在一个小小的房间里. 改善洛萨坦的抗高血压活性
Pedro de Padua G Amatto1, Juliana da Silva Coppede1, Carla Renata Kitanishi1
1Department of Biotechnology of Medicinal Plants, University of Ribeirão Preto, Ribeirão Preto 14096-900, Brazil.
Molecules (Basel, Switzerland)
|January 8, 2025
概括
卡兰霍 (Kalanchoe crenata) 提取物与洛萨坦 (losartan) 结合,在治疗高血压方面显示出有前途. 这种草药在高血压大鼠中显著降低了血压和MMP2活性.
科学领域:
- 植物化学和药理学
- 心血管研究研究心血管研究
- 草药是一种草药.
背景情况:
- 心血管疾病是全球主要的死亡原因.
- 草药为合成高血压药物提供了潜在的替代品.
- 卡兰 (Kalanchoe crenata) 是因为其药用特性而被探索的.
研究的目的:
- 隔离并识别Kalanchoe crenata的化学标记物.
- 研究Kalanchoe crenata叶提取物的抗高血压活性.
- 评估提取物对抗矩阵金属蛋白酶 (MMP2) 的活性.
主要方法:
- 使用UPLC-MS和NMR光谱分析的K.crenata的水性提取物.
- 在Wistar大鼠中诱导的再生血管高血压 (双脏单片式模型).
- 小鼠接受了K.crenata提取物,洛萨坦或其组合的治疗,持续了8周.
主要成果:
- 确定了帕图莱丁衍生物和跨咖啡-酸作为关键化合物.
- 化合物1和2被证实是K.crenata的化学标记物.
- 在接受K.crenata和洛萨坦治疗的老鼠中,缩血压和MMP2活性显著降低.
结论:
- 卡兰 (Kalanchoe crenata) 提取物与洛萨坦结合,在体内表现出抗高血压作用.
- 组合疗法显示出管理高血压的潜力.
- 进一步研究K. crenata作为辅助治疗是有必要的.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
579
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
579
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
472
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
472
Antihypertensive Drugs: Potassium-Sparing Diuretics
445
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
445
Antihypertensive Drugs: Direct Renin Inhibitors
484
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
484
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338


